Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics

Journal of Clinical Pathology

Volumn 68, Issue 10, 2015, Pages 766-770

  Elliott, Kelly ^a   McQuaid, Stephen ^b   Salto Tellez, Manuel ^b   Maxwell, Perry ^b  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; KI 67 ANTIGEN; PROTEIN P53; BIOLOGICAL MARKER; TP53 PROTEIN, HUMAN;

ACCURACY; ARTICLE; CLINICAL PROTOCOL; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; REPRODUCIBILITY; STANDARD; VALIDATION PROCESS; OBSERVER VARIATION; PRACTICE GUIDELINE; PREDICTIVE VALUE; STANDARDS; WORKFLOW;

BIOMARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MOLECULAR DIAGNOSTIC TECHNIQUES; OBSERVER VARIATION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TUMOR SUPPRESSOR PROTEIN P53; WORKFLOW;

EID: 84943454175     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2015-203178     Document Type: Article

References (32)

1. Rakha EA, Pinter SE, Bartlett JM, et al. Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol 2015;68:93-9.
2. National Institute for Health and Clinical Excellence. Diagnostics Assessment Programme. Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimes in breast cancer management. 2013. http://www. nice. org. uk/guidance/dg10 (accessed Apr 2015).
3. National Institute for Health and Clincial Excellence. Final appraisal determination; Crizotinib for previously treated non small cell lung cancer associated with anaplastic lymphoma kinase fusion gene. 2013. http://www. nice. org. uk/guidance/ta296 (accessed Apr 2015).
4. McCourt CM, Boyle D, James J, et al. Immunohistochemistry in the era of personalised medicine. J Clin Pathol 2013;66:58-61.
5. Iacopetta. TP53 mutation in colorectal cancer. Hum Mutat 2003;21:271-6.
6. Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res 2011;110:108.
7. Riley T, Sontag E, Chen P, et al. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12.
8. Gannon JV, Greaves R, Iggo R, et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-602.
9. Kerns BJ, Jordan PA, Moore MB, et al. P53 Overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992;40:1047-51.
10. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
11. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-9.
12. Allegra CJ, Paik S, Colangelo IH, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003;21:241-50.
13. McCluggage WG, Connolly LE, McGregor G, et al. A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. J Gynecol Surg 2005;24:307-12.
14. Hall PA, McCluggage WG. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J Pathol 2006;208:1-6.
15. Bahnassy AA, Zekri AR, Salem SE, et al. Differential expression of p53 family proteins in colorectal adenomas and carcinomas: Prognostic and predictive values. Histol Histopathol 2014;29:207-16.
16. Decastel M, Ossondo M, Andrea A, et al. Colorectal cancer in patients seen at the teaching hospitals of Guadeloupe and Martinique: discrepancies, similarities in clinicopathological features, and p53 status. BMC Clin Pathol 2014;14:12.
17. Malhotra P, Anwar M, Nanda N, et al. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumour Biol 2013;34:1901-11.
18. Varga Z, Diebold J, Dommann-Scherrer C, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast and Gynecopathologists. PLoS ONE 2012;7:e37379.
19. Resnick MB, Routhier J, Konkin T, et al. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004;10:3069-75.
20. Samowitz WS, Holden JA, Curtin K, et al. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol 2001;158:1517-24.
21. Takahashi Y, Bucana CD, Cleary KR, et al. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 1998;79:34-8.
22. Lenz HJ, Danenberg KD, Leichman CG, et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998;4:1227-34.
23. Rodrigues NR, Rowan A, Smith ME, et al. P53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990;87:7555-9.
24. Dowsett M, Nielson TO, A'Hern R, et al. International Ki-67 in breast cancer working group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011;103:1656-64.
25. Polley MY, Leung SC, McShane LM, et al. International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. An international Ki67 reproducibility study. J Natl Cancer Inst 2013;105:1897-906.
26. Carlson RW, Allred DC, Anderson BO, et al. National Comprehensive Cancer Network. Invasive breast cancer. J Natl Compr Canc Netw 2011;9:136-222.
27. Harris L, Fritsche H, Mennel R, et al, American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
28. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52.
29. Bordeaux J, Welsh A, Agarwal S, et al. Antibody validation. BioTechniques 2010;48:197-201.
30. Ilyas M, Grabsch H, Elis I, et al. Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology 2013;62:827-39.
31. Hardy LB, Fitzgibbons PL, Goldsmith JD. Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories. Arch Pathol Lab Med 2013;137:19-25.
32. Mattocks CJ, Morris MA, Matthijs G, et al. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet 2010;18:1276-88.